Vericel Corporation (VCEL) Receives Daily News Sentiment Score of 0.15
Media stories about Vericel Corporation (NASDAQ:VCEL) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vericel Corporation earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.7709303621463 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Short Interest in Vericel Corporation (VCEL) Declines By 23.5% (americanbankingnews.com)
- Vericel Corporation (NASDAQ:VCEL) Sees Stock Price Rise – Up by 8.04% – First News 24 (firstnewspaper24.com)
- BTIG Reiterates Bullish Stance on Vericel Corp (VCEL) Following Investor Meetings with Management – Smarter Analyst (smarteranalyst.com)
- Vericel Corp Higher For Fourth Day In A Row – Benzinga (benzinga.com)
- Vericel to Present at the 2017 Cell & Gene Meeting on the Mesa (globenewswire.com)
A number of research analysts have recently commented on the company. BTIG Research assumed coverage on Vericel Corporation in a report on Tuesday, June 20th. They set a “buy” rating and a $6.00 price objective on the stock. Piper Jaffray Companies reissued a “buy” rating and set a $7.00 price objective on shares of Vericel Corporation in a report on Thursday, August 10th.
Vericel Corporation (NASDAQ:VCEL) opened at 6.00 on Friday. The stock’s 50 day moving average price is $3.81 and its 200-day moving average price is $3.11. Vericel Corporation has a one year low of $2.00 and a one year high of $6.30. The firm’s market cap is $196.94 million.
Vericel Corporation (NASDAQ:VCEL) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.16. The company had revenue of $16.95 million for the quarter. Analysts forecast that Vericel Corporation will post ($0.63) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/vericel-corporation-vcel-receives-daily-news-sentiment-score-of-0-15/1600760.html.
About Vericel Corporation
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.